出海

Search documents
张华薇:企业出海一定要有合规意识,需避五大风险
Feng Huang Wang Cai Jing· 2025-07-01 09:06
第一,要高度尊重重当地文化和宗教。张华薇表示,在中东国家,宗教法律与社会规范深度绑定,涉及宗教事务的服务需提前向当地宗教部门申请许可,避 免以 "低价"、"便捷" 等噱头进行商业宣传,需充分尊重当地宗教神秘性与法律的刚性规定; 第二,要充分做好市场准入调研。张华薇表示中东地区的外资准入制度向日益鼓励外商投资演变,比如阿联酋2018年新修订的《外国直接投资法》;部分领 域突破了先前要求本国资本在阿联酋境内设立的公司中所占股份不得低于51%的规定,2019年阿联酋又公布了允许外资100%投资的行业(正面清单); 2020年《新商业公司法》出台取代了原《外国直接投资法》,允许外资在绝大部分领域拥有在岸公司100%所有权;2021年宣布了对外资进行限制的领域清 单,六个领域包括涉及国际安全与国防、银行、外汇、金融机构与保险、印刷货币、通讯传播、朝觐与副朝觐相关服务业、古兰经诵经机构等为批准制度, 而渔业相关服务业则为禁止行业。 凤凰网财经讯 6月28-29日,"2025中国企业出海高峰论坛"在深圳举行,本次论坛由凤凰网主办,雪花超高端系列品牌-醴首席赞助合作,中国企业出海全球 化理事会联合主办,以"为开放的世界"为主 ...
雷军距离马斯克有多远?
Sou Hu Cai Jing· 2025-07-01 08:13
Core Insights - Xiaomi's YU7 SUV is positioned as a direct competitor to Tesla's Model Y, with a starting price of 253,500 RMB, only 10,000 RMB cheaper than Model Y [4][16] - The initial demand for YU7 is significant, with over 200,000 pre-orders within three minutes and 240,000 within 18 hours, indicating a strong market entry [4][14] - Tesla is facing challenges in maintaining its market dominance due to increasing competition from Chinese manufacturers like Xiaomi, especially in key markets such as China and Europe [16][17] Company Analysis - Xiaomi's YU7 launch has generated considerable attention, with comparisons to Tesla's Model Y and discussions about its potential impact on Tesla's market share [3][5] - The company aims to deliver 350,000 vehicles this year, with the YU7 being a crucial part of this strategy [8][14] - Xiaomi's future plans include expanding into international markets by 2027, which could further challenge Tesla's position [15][17] Industry Trends - The automotive industry is witnessing a shift with increased competition from Chinese manufacturers, leading to a decline in Tesla's sales in Europe and China [16] - Tesla's sales in Europe dropped by 27.9% in May, highlighting the impact of competition from companies like BYD and SAIC [16] - The introduction of lower-priced models by Tesla, such as the potential Model Y "Youth Edition," is seen as a necessary response to the competitive pressure from Xiaomi and other Chinese automakers [18]
2025华东制造业CIO沙龙将于7月19日在宁波召开
Huan Qiu Wang· 2025-07-01 07:23
Group 1 - The 2025 East China Manufacturing CIO Salon will be held on July 19, 2025, in Ningbo, focusing on "Going Global & AI" to create a platform for exchange and cooperation among manufacturing pioneers and experts [1][3] - The event aims to address the challenges faced by manufacturing companies in IT infrastructure, data compliance, system integration, and cultural differences while exploring the transformative impact of AI technology on production processes and operational efficiency [3][4] - The salon will feature high-profile guests from renowned manufacturing companies such as BYD, Tianneng Group, Wanxiang Qianchao, and others, sharing their insights on going global, AI applications, and digital transformation [4][5] Group 2 - The agenda will cover a wide range of topics, including practical sharing on digital transformation, considerations for IT in going global, applications of AIGC in manufacturing, and how AI+BI can help reduce costs and increase efficiency [5] - A discussion session for all CIOs will be included to address specific challenges and solutions related to going global and AI in manufacturing [5][6] - The event is organized by leading IT portal D1net, the CIO intelligence platform Xinzongzhi, and the China Enterprise Digitalization Alliance, which aims to support companies undergoing digital transformation [6]
破局跨境流量困局:鲁班跨境通4大核心服务助力品牌出海
Zhong Guo Chan Ye Jing Ji Xin Xi Wang· 2025-07-01 07:12
Core Insights - The 2023 China Cross-Border E-commerce White Paper highlights a key trend where independent sellers using a combination of "SEO + social media + influencers" have reduced customer acquisition costs by 18% compared to platform sellers [1] Group 1: Company Overview - Luban Cross-Border Pass, a one-stop overseas marketing service platform under BlueFocus Media, has established a comprehensive empowerment system covering "traffic acquisition - operational conversion - capability growth" [1][13] - The platform has assisted over 50,000 Chinese enterprises in overcoming growth bottlenecks in international markets [1][13] Group 2: Services Offered - The platform offers a "0 service fee + fast account opening" green channel, allowing new customers to complete account verification in as little as 3 working days, which is three times faster than the industry average [2] - Multiple payment methods are supported, including Payoneer, Alipay, WeChat, and PingPong, facilitating transactions in both USD and RMB [2] Group 3: Performance Metrics - A 3C category independent seller utilized the platform's multi-currency real-time recharge feature during the Black Friday promotion, achieving a 15% market share in their niche within the first week of launching a hot-selling product [4] - A home goods brand achieved a 65% increase in CTR and a 32% reduction in customer acquisition costs through targeted Google search ads using a "long-tail keyword + dynamic landing page" strategy [5] Group 4: Media Resource Integration - Luban Cross-Border Pass has integrated resources from major and emerging media, creating a comprehensive traffic matrix that includes social (Meta, TikTok), search (Google, Bing), video (YouTube, BIGO Ads), and niche platforms (Pinterest, Snapchat) [7] - A fast-moving consumer goods brand increased brand exposure by 400% and achieved over 100,000 sales in the first month of a new product launch through a combination strategy involving TikTok, Pinterest, and Taboola [7] Group 5: Training and Support - The platform has developed a three-dimensional training system covering "theoretical learning - practical training - community exchange," offering weekly free live courses on advanced advertising techniques [9] - A specialized "Overseas Advertising Entry Program" is available for novice sellers, providing a 7-day course to teach them the entire process from website monitoring to data optimization [10]
2025年第25周:跨境出海周度市场观察
艾瑞咨询· 2025-07-01 07:00
跨境出海丨市场观察 本周看点: -四川"智造"打开新空间:智能机器人、低空飞行器加速出海; -穿越红利周期,中国App如何突围全球增长新格局; -高增长按下暂停键,2025成跨境分水岭。 行业环境 1.四川"智造"打开新空间:智能机器人、低空飞行器加速出海 关键词 : 智能机器人,低空经济,科技创新,出海合作,一带一路 概要 : 第二届"一带一路"科技交流大会在成都举行,聚焦四川人工智能与低空经济等新兴产业 的国际合作。协作机器人、水下机器人和无人机等"智造"产品加速出海,与沿线国家深化合 作。天链、潜行科技等企业实现规模化商用,傲势科技海外订单增长显著。同时,四川打造低 空经济发展高地,民航二所展示低空交通管理平台提升安全监管能力,强调电子通讯安全与技 术融合。四川以科技创新推动新兴产业全球化布局,注重安全有序发展。 2.北京大兴国际机场临空经济区跨境电商产业迎来高速增长 带动河北特色产业集 群"品牌出海" 关键词 : 跨境电商,临空经济区,品牌出海,国际贸易,数字化转型 概要 : 北京大兴国际机场临空经济区举办跨境电商产业交流会,透露2024年跨境电商进出口 值同比增长超120%,注册企业达14500家。 ...
兼“新消费50”组合与十五大启示:新时期消费投资总论:巴菲特“破防”了么?
Zhao Shang Yin Hang· 2025-07-01 06:00
2025 年 07 月 01 日 新时期消费投资总论:巴菲特"破防"了么?—兼"新消费 50"组合 与十五大启示 在过去相当长时间内,资本市场自上而下对于消费定价的第一性原理的理论基础 是基于经济学,表现为消费是经济和收入的函数,基于此的消费定价在过去屡试不 爽。伴随着城镇化加速与中产阶级加速崛起的过程,2010-2022 年长达十余年间 A 股关于消费定价始终围绕着"消费升级"主线,一路带来"2010 年五朵金花"、"2017 年漂亮 50"、"2019-2020 年茅指数"等诸多高光时刻,而伴随着中国房地产在 2021 年步入深入调整,居民消费心智的变迁,A 股以白酒为代表的传统消费投资逐渐黯 淡,而包括泡泡玛特、老铺黄金在内的新消费定价风起云涌。在这一过程中,我们 认为当前消费投资已经步入新时期,需要对新时期消费投资进行重塑: 1、消费投资的变化诱因:历史回顾比较看,在长时间序列更广谱的国家中,随着 经济的发展都有一段中产阶级崛起的过程,中产的消费变迁在一定程度上也代表 了整体消费定价趋势。从海外经验看,当中产阶级出现波动,消费投资或有新特征。 当然,面对国内中产阶级未来中期趋势,当前我国正加速产业升级 ...
生物医药ETF(512290)涨超1.2%,减重药突破与估值低位引关注
Mei Ri Jing Ji Xin Wen· 2025-07-01 05:59
消息面上,2025年6月30日生物医药产业资本对接会成功举办,促进产融合作。此外,6月24日,市药品 监督管理局在宝山高新区举办第三期生物医药产品"注册讲堂",聚焦无源/有源器械及体外诊断试剂检 测与临床评价要点,为80余家医疗器械企业提供政策指导。 注:如提及个股仅供参考,不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考,不预示 未来表现。市场观点随市场环境变化而变动,不构成任何投资建议或承诺。文中提及指数仅供参考,不 构成任何投资建议,也不构成对基金业绩的预测和保证。如需购买相关基金产品,请选择与风险等级相 匹配的产品。基金有风险,投资需谨慎。 (文章来源:每日经济新闻) 东莞证券指出,医药生物板块近期迎来回调,此前涨幅较大的创新药相关产业链和减肥药板块跌幅居 前。目前国内创新药公司经过多年研发投入,陆续进入收获期,创新药领域近期利好频出,新药出海授 权金额不断创新高,创新药业务开始为创新药企业贡献业绩。SW医药生物行业近期下跌5.05%,跑输 同期沪深300指数约6.43个百分点,三级细分板块全部录得负收益,其中医疗耗材和医院板块跌幅较 少,化学制剂和线下药店板块跌幅居前。行业估值有所下降,目 ...
医药生物行业周报:《2025年基本医保目录及商保创新药目录调整申报操作指南》出炉,继续看好创新药-20250701
Guoyuan Securities· 2025-07-01 05:53
[Table_Main] 行业研究|医疗保健 证券研究报告 本周神州细胞、浩欧博和华人健康等表现较好 涨幅排名前十的个股分别为:神州细胞(+30.45%)、浩欧博 (+27.08%)、华人健康(+26.00%)、华强科技(+22.94%)、迈威生 物(+17.44%)、南模生物(+16.51%)、锦好医疗(+16.05%)、百普 赛斯(+15.79%)、塞力医疗(+14.49%)、贵州百灵(+12.80%)。 跌幅排名前十的个股分别为:易明医药(-21.91%)、福元医药(- 11.50%)、博瑞医药(-9.36%)、悦康药业(-7.74%)、*ST 赛隆(- 6.87%)、众生药业(-6.04%)、常山药业(-5.93%)、科兴制药(-5.77%)、 圣诺生物(-5.12%)、赛升药业(-4.73%)。 医疗保健行业周报 2025 年 07 月 01 日 [Table_Title] 《2025 年基本医保目录及商保创新药目录调 整申报操作指南》出炉,继续看好创新药 ——医药生物行业周报(2025.6.23-2025.6.27) [Table_Summary] 报告要点: 医药板块本周跑输沪深 300 指数 ...
重磅利好,突袭!刚刚,集体大涨!
券商中国· 2025-07-01 03:43
创新药板块,迎来重磅利好! 7月1日最新消息,国家医保局、国家卫生健康委印发《支持创新药高质量发展的若干措施》(以下简称《若干 措施》)。其中提出,支持医保数据用于创新药研发,鼓励商业健康保险扩大创新药投资规模,有针对性地加 强创新药在药品目录准入方面的政策指导。 组织实施创新药物研发国家科技重大专项,聚焦重大传染病、高发重大慢性病、儿童用药、罕见病等重点领 域,推动药物研发相关任务落地实施并完善多部门联动的支持机制。发挥国家医学中心和国家临床医学研究中 心作用,依托国家科技重大专项、重点研发计划等,支持医药企业、科研院所、医疗机构等开展以创新药研发 为导向的科研攻关。 在上述消息的刺激下,7月1日早盘,创新药概念股集体拉升,塞力医疗、贵州百灵涨停,舒泰神涨近12%,热 景生物涨近10%。 有券商指出,2025年预计是国内创新药授权出海的重要年份,技术创新+市场扩容引领创新药产业趋势行情, 持续看好后续催化与兑现。 创新药板块迎来重磅利好 自今年5月中旬以来,创新药概念股持续走强,虽然中途曾出现高位调整,但最近几个交易日又再度活跃起 来。7月1日早间,创新药板块再度拉升,截至中午收盘,塞力医疗、贵州百灵涨停, ...
科创生物医药ETF(588250)上涨近1%,药品追溯码全面应用
Sou Hu Cai Jing· 2025-07-01 02:12
Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index (000683) increased by 0.93% as of July 1, 2025, with notable gains from stocks such as Rongchang Biopharmaceutical (688331) up 7.21% and Shanghai Yizhong (688091) up 3.61% [1] - Starting July 1, 2025, a new policy mandates that all drug sales must include a verification code for medical insurance reimbursement, with full traceability of drug codes required by January 1, 2026, which is expected to enhance drug circulation regulation and impact the entire pharmaceutical industry chain [1] - The current bull market in innovative drugs is driven by the improvement of China's pharmaceutical innovation capabilities, with a trend towards international collaboration in new drug development expected to enhance profitability and market potential for Chinese pharmaceutical companies [2] Group 2 - As of June 30, 2025, the top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index accounted for 50.3% of the index, including companies like United Imaging Healthcare (688271) and BeiGene (688235) [3] - The Sci-Tech Biopharmaceutical ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in various biopharmaceutical sectors [2]